WithdrawnPhase 2NCT04832438
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Studying Adenoid cystic carcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Actuate Therapeutics Inc.
- Principal Investigator
- Glenn J Hanna, MD, MDDana-Farber Cancer Institute
- Intervention
- 9-ING-41(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2030 – 2034
Study locations (1)
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04832438 on ClinicalTrials.govOther trials for Adenoid cystic carcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07507578A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic CarcinomaFondazione IRCCS Istituto Nazionale dei Tumori, Milano
- RECRUITINGPHASE2NCT06781567Clinical Trial of HG146 Administered to Participants with Adenoid Cystic CarcinomaHitGen Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT04209660Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT04214366Adenoid Cystic Carcinoma and Carbon Ion Only IrradiationHeidelberg University
- RECRUITINGPHASE1, PHASE2NCT03556228VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaVM Oncology, LLC
See all trials for Adenoid cystic carcinoma of the cervix uteri →